RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Nabriva Therapeutics Stock

Nabriva Therapeutics P/S 2024

Nabriva Therapeutics P/S

0.01

Ticker

NBRV

ISIN

IE00BL53QQ85

WKN

A2QKWR

As of Jul 31, 2024, Nabriva Therapeutics's P/S ratio stood at 0.01, a -83.33% change from the 0.06 P/S ratio recorded in the previous year.

The Nabriva Therapeutics P/S history

Nabriva Therapeutics Aktienanalyse

What does Nabriva Therapeutics do?

Nabriva Therapeutics PLC is a biopharmaceutical company based in Dublin that focuses on the research, development, and marketing of antibiotics for medical needs. The company was founded in 2006 and has since become the leading provider of antibiotics for infectious diseases in Europe and the USA. Nabriva Therapeutics' business model aims to improve the production of antibiotics for acute infections and develop innovative drugs for use in clinical practice and emergency settings. It specializes in serious and life-threatening infections such as pneumonia, bacterial skin and soft tissue infections, and bacterial infections of the urinary tract. The company is divided into two business segments: antibody therapeutics and antibiotics. Antibody therapeutics stimulate the body's immune system to better fight pathogens, while antibiotics directly combat and inhibit the growth of bacteria. Nabriva Therapeutics' flagship product is the antibiotic Xenleta (Levofloxacin) for the treatment of pneumonia. Xenleta is a bactericidal antibiotic that is effective against a variety of difficult-to-treat pathogens such as Methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus with reduced susceptibility to Vancomycin (VSSA), acting directly on bacteria. It has been reviewed and approved by the FDA. Nabriva Therapeutics has also advanced the development of Contepo (Fosfomycin) in the field of antibiotics. Contepo is a broad-spectrum antibiotic that is effective against gram-positive and gram-negative bacteria and is intended for the treatment of infectious diseases of the urinary tract. Nabriva Therapeutics has submitted a support application to the FDA for the approval of Contepo for the therapy of complicated urinary tract infections. In August 2020, Nabriva Therapeutics announced the completion of an agreement with Taiho Pharmaceutical Co., Ltd. to market Xenleta in Brazil. The company has also entered into a collaboration with Merck and Co.'s biopharmaceutical organization to investigate the potential of Xenleta for treating patients with diseases such as bacterial skin and soft tissue infections and lung infections. Overall, Nabriva Therapeutics has played an important role in the development of antibiotics for infectious diseases and the fight against antibiotic resistance. With its innovative products and collaboration with other biopharmaceutical organizations, Nabriva Therapeutics has improved its position in the industry and strengthened its leadership in the field of antibiotic therapy. Nabriva Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Nabriva Therapeutics's P/S Ratio

Nabriva Therapeutics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Nabriva Therapeutics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Nabriva Therapeutics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Nabriva Therapeutics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Nabriva Therapeutics stock

What is the price-to-earnings ratio of Nabriva Therapeutics?

The price-earnings ratio of Nabriva Therapeutics is currently 0.01.

How has the price-earnings ratio of Nabriva Therapeutics changed compared to last year?

The price-to-earnings ratio of Nabriva Therapeutics has increased by -83.33% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Nabriva Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Nabriva Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Nabriva Therapeutics affect the company?

An increase in the price-earnings ratio of Nabriva Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Nabriva Therapeutics affect the company?

A decrease in the price-earnings ratio of Nabriva Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Nabriva Therapeutics?

Some factors that influence the price-earnings ratio of Nabriva Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Nabriva Therapeutics pay?

Over the past 12 months, Nabriva Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nabriva Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Nabriva Therapeutics?

The current dividend yield of Nabriva Therapeutics is .

When does Nabriva Therapeutics pay dividends?

Nabriva Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nabriva Therapeutics?

Nabriva Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Nabriva Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nabriva Therapeutics located?

Nabriva Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Nabriva Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nabriva Therapeutics from 7/31/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/31/2024.

When did Nabriva Therapeutics pay the last dividend?

The last dividend was paid out on 7/31/2024.

What was the dividend of Nabriva Therapeutics in the year 2023?

In the year 2023, Nabriva Therapeutics distributed 0 USD as dividends.

In which currency does Nabriva Therapeutics pay out the dividend?

The dividends of Nabriva Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Nabriva Therapeutics

Our stock analysis for Nabriva Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nabriva Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.